Douglas Dorsey
Pulmonary Disease · Salem, VANPI 1861437592
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 994 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $5,012 and has fallen 99.6% since, to $22 in 2025.
Across 994 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Actelion Pharmaceuticals US, Inc.$1K
- Boehringer Ingelheim$1K
- Genentech USA, Inc.$1K
- Sanofi$1K
- plus $8K from 33 others
What the payments were for
- Consulting fees$140%
- Food & beverage$16,89996%
- Education$7504%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 193 | $2,191 |
| AstraZeneca | 104 | $2,107 |
| Actelion Pharmaceuticals US, Inc. | 56 | $1,395 |
| Boehringer Ingelheim | 71 | $1,369 |
| Genentech USA, Inc. | 58 | $1,266 |
| Sanofi | 50 | $1,117 |
| Mylan Specialty L.p. | 58 | $1,065 |
| Mallinckrodt Hospital Products Inc. | 60 | $958 |
| United Therapeutics Corporation | 40 | $859 |
| Regeneron Healthcare Solutions, Inc. | 24 | $580 |
| Sunovion Pharmaceuticals Inc. | 37 | $551 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $542 |
| Novartis | 25 | $444 |
| Teva Pharmaceuticals USA, Inc. | 26 | $378 |
| La Jolla Pharmaceutical Company | 17 | $248 |
| Grifols USA, LLC | 11 | $245 |
| Merck | 15 | $228 |
| ANI Pharmaceuticals, Inc. | 8 | $203 |
| Johnson & Johnson(2 entities) | 14 | $202 |
| Insmed, Inc. | 12 | $196 |
| Amgen | 10 | $167 |
| Sanofi-aventis U.S. LLC | 2 | $162 |
| Mallinckrodt Enterprises LLC | 13 | $159 |
| Inogen, Inc. | 8 | $144 |
| Gilead | 8 | $131 |
| Pulmonx Corporation | 3 | $125 |
| E.r. Squibb & Sons, L.L.C. | 9 | $121 |
| Electromed, Inc. | 9 | $113 |
| Baxter Healthcare | 5 | $92 |
| Bayer | 5 | $84 |
| Shire North American Group Inc | 3 | $44 |
| Philips North America LLC | 3 | $40 |
| Pharming Healthcare, Inc. | 2 | $37 |
| CSL Behring | 1 | $24 |
| Inari Medical, Inc. | 1 | $21 |
| Acacia Pharma Inc | 1 | $17 |
| Itamar Medical Inc | 1 | $14 |
| Pfizer | 1 | $14 |
| Vapotherm Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,664 in reported general payments places this provider in the 85th percentile of 317 pulmonary disease providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 111 | $84,916 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $27,562 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $25,857 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $22,489 |
| Spiriva RespimatTiotropium Bromide | 35 | $20,005 |
| Spiriva HandihalerTiotropium Bromide | 22 | $19,572 |
| SymbicortBudesonide/Formoterol Fumarate | 55 | $18,841 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $16,614 |
| Advair HfaFluticasone Propion/Salmeterol | 25 | $10,591 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $6,267 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 95 | $3,266 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $1,969 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $1,638 |
| Montelukast Sodium | 69 | $659 |
| Prednisone | 16 | $77 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $2,191 | $139,530215 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,107 | $46,40496 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $1,369 | $36,61965 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Salem
- James WittenSalem$119K
- David KilleenSalem$47K
- Nelson GreeneSalem$31K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.